| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Jan 10, 2019 | AMRN Amarin Corp Plc\uk | Stack David M67 | Director | Sell | 125,504 | $18.00 | $2,259,072.00 | -100% | |
| Jan 10, 2019 | AMRN Amarin Corp Plc\uk | Zakrzewski Joseph S55 | Director | Sell | 200,000 | $16.98 | $3,396,390.00 | -42.6% | |
| Jan 10, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Obus Nelson | Director | Buy | 20,000 | $11.33 | $226,600.00 | +0.7% | |
| Jan 10, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Sohn Catherine A.55 | Director | Buy | 1,000 | $11.23 | $11,230.00 | +4.2% | |
| Jan 9, 2019 | AMRN Amarin Corp Plc\uk | Kalb Michael Wayne | SVP And CFO | Sell | 200,000 | $15.26 | $3,051,080.00 | -92.0% | |
| Jan 9, 2019 | PAHC Phibro Animal Health Corp | Bendheim Daniel M | Exec. VP, Corporate Strategy | Sell | 5,000 | $32.43 | $162,125.00 | -100% | |
| Jan 8, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Goldby Steven D | Director | Buy | 20,000 | $11.24 | $224,800.00 | +43.0% | |
| Jan 8, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Skinner Gregory S | Chief Financial Officer | Buy | 25,000 | $11.25 | $281,250.00 | +9.5% | |
| Jan 8, 2019 | LFCR Lifecore Biomedical, Inc. \de\ | Carosella Deborah D | Director | Buy | 4,500 | $11.34 | $51,030.00 | +52.8% | |
| Jan 8, 2019 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 1,857 | $84.09 | $156,158.66 | -37.1% | |
| Jan 7, 2019 | PAHC Phibro Animal Health Corp | Bendheim Daniel M | Exec. VP, Corporate Strategy | Sell | 7,500 | $31.74 | $238,075.00 | -100% | |
| Jan 4, 2019 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 80,000 | $41.29 | $3,303,256.00 | +2.4% | |
| Jan 4, 2019 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $30.00 | $30,000.00 | -100% | |
| Jan 3, 2019 | EGRX Eagle Pharmaceuticals, Inc. | Tarriff Scott | CEO | Sell | 31,569 | $39.49 | $1,246,763.02 | -0.4% | |
| Jan 2, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, SVP &Treasurer | Sell | 3,245 | $19.52 | $63,354.41 | -4.1% | |
| Jan 2, 2019 | HROW Harrow, Inc. | Kammer Robert J | Director | Sell | 10,000 | $5.33 | $53,300.00 | -1.1% | |
| Jan 2, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 1,643 | $15.70 | $25,799.21 | -12.2% | |
| Jan 2, 2019 | AMRN Amarin Corp Plc\uk | Zakrzewski Joseph S55 | Director | Sell | 526,500 | $13.07 | $6,882,371.00 | -75.7% | |
| Jan 2, 2019 | CPMD Cannapharmarx, Inc. | Herick Gary J | Chief Financial Officer | Buy | 600,000 | $2.00 | $1,200,000.00 | +66.7% | |
| Dec 31, 2018 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 17,041 | $13.51 | $230,211.98 | -4.8% | |
| Dec 31, 2018 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 26,943 | $13.49 | $363,547.29 | -11.0% | |
| Dec 31, 2018 | HSTI High Sierra Technologies, Inc. | Vardakis Michael | Director | Buy | 1,087,525 | $0.02 | $21,750.50 | +142.6% | |
| Dec 31, 2018 | SCYX Scynexis Inc | Taglietti Marco | Chief Executive Officer | Buy | 25,000 | $0.46 | $11,500.00 | +5.8% | |
| Dec 31, 2018 | SCYX Scynexis Inc | Angulo Gonzalez David | Chief Medical Officer | Buy | 12,000 | $0.50 | $5,950.80 | +10.9% | |
| Dec 28, 2018 | UTHR United Therapeutics Corp | Patusky Christopher50 | Director | Sell | 17 | $111.37 | $1,893.29 | -0.3% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.